Table 1 Patient characteristics
Demographic Covariates Categorical | n (%) | |
Tumor Type | ||
 NSCLC all types | 158 (71.5) | |
  Non-Squamous | 96 | |
  Squamous | 42 | |
  Unknown NSCLC type | 20 | |
 Melanoma | 48 (21.7) | |
 RCC | 14 (6.3) | |
 Mesothelioma | 1 (0.5) | |
Treatment | ||
 Nivolumab monotherapy (3 mg/kg Q2W) | 221 (100) | |
Gender | ||
 Male | 138 (62.4) | |
 Female | 83 (37.6) | |
Race | ||
 Caucasian | 195 (88.2) | |
 Other | 5 (2.3) | |
 Unknown | 21 (9.5) | |
WHO Performance Status | Â | |
 0 | 63 (28.5) | |
 1 | 103 (46.6) | |
 2 | 4 (1.8) | |
 Unknown | 51 (23.1) | |
Weight loss prior to start therapy (only in NSCLC) | ||
 Yes | 36 (16.3) | |
 No | 81 (36.7) | |
 Unknown | 104 (47.1) | |
Demographic and Laboratory Covariates Continuous | Median (IQR) | n (%) |
 Age (yr) | 65 (59–71) | 221 (100) |
 Body Weight (kg) | 78.5 (70–88) | 220 (99.5) |
 Body Surface Area (m2) | 1.95 (1.81–2.09) | 205 (93) |
 Tumor Burden 3D (cm3; only in NSCLC) | 18.6 (66–98) | 25 (11) |
 Creatinine (μmol/L) | 81 (66–98) | 203 (92) |
 CKD (mL/min) | 81 (62–90) | 203 (92) |
 Total Protein (g/L) | 73 (69–90) | 163 (74) |
 Albumin (g/L) | 42 (42–45) | 174 (79) |
 LD (U/L) | 215 (183–275) | 196 (89) |
 Leucocytes (109 cells/L) | 7.7 (6.3–10.2) | 203 (92) |